Enfuvirtide

GPTKB entity

Statements (57)
Predicate Object
gptkbp:instance_of gptkb:drug
gptkbp:activities fusion inhibitor
prevents viral entry into cells
gptkbp:appointed_by subcutaneous injection
gptkbp:approves gptkb:2003
gptkb:FDA
gptkbp:availability prescription only
gptkbp:brand Fuzeon
gptkbp:can_be_used_with other antiretroviral agents
gptkbp:class HIV fusion inhibitors
gptkbp:clinical_trial Phase III
HIV infection
ongoing for new indications
gptkbp:contraindication hypersensitivity to the drug
gptkbp:developed_by Trimeris
gptkbp:dosage_form lyophilized powder for injection
gptkbp:duration long-term therapy
gptkbp:education necessary for proper use
gptkbp:established gp41 protein
gptkbp:formulation injectable
powder for reconstitution
https://www.w3.org/2000/01/rdf-schema#label Enfuvirtide
gptkbp:indication treatment-experienced HIV patients
gptkbp:ingredients gptkb:Enfuvirtide
C37 H48 N6 O9 S
gptkbp:interacts_with none significant
gptkbp:invention patented
gptkbp:is_monitored_by regular follow-up required
gptkbp:is_used_for treatment of HIV
gptkbp:lifespan 3.8 hours
gptkbp:manager subcutaneous
gptkbp:marketed_as gptkb:Roche
gptkbp:pharmacokinetics subcutaneous absorption
inhibits HIV fusion process
gptkbp:population adults and children
gptkbp:price expensive
gptkbp:provides_access_to limited in some regions
gptkbp:provides_information_on included in treatment guidelines
part of combination therapy
gptkbp:research_focus HIV resistance
gptkbp:rounds renal
gptkbp:safety_features generally well tolerated
gptkbp:side_effect fatigue
nausea
diarrhea
injection site reactions
increased risk of bacterial pneumonia
gptkbp:status ongoing studies
gptkbp:storage refrigerated
gptkbp:supply_chain complex logistics required
gptkbp:targets HIV-1 virus
gptkbp:traded_on Fuzeon
gptkbp:type_of_care important for effectiveness
gptkbp:weight 659.96 g/mol
gptkbp:year_created gptkb:1992
gptkbp:bfsParent gptkb:Burroughs_Wellcome
gptkbp:bfsLayer 4